Neuroone Medical Technologies (NMTC) Status Update summary

Fiscal 2025 Strategic Plan and Business Overview

• Focus on expanding the OneRF ablation system, with comprehensive updates on fiscal 2025 plans and technology.

• Transforming neurological disorder treatment with FDA-cleared thin-film electrode technology and three 510(k) cleared product families.

• Exclusive partnerships with Mayo Clinic and Zimmer Biomet support commercialization, clinical research, and product development.

• Target markets include epilepsy, brain ablation, Parkinson’s, spinal cord stimulation, pain management, and future drug delivery.

• Patented technology targets multi-billion dollar neurology markets and is supported by a strong management and advisory team.

Product and Technology Developments

• OneRF ablation system enables both diagnostic and therapeutic use, reducing hospitalizations and improving outcomes.

• Evo Cortical and SEEG electrodes distributed by Zimmer Biomet offer improved signal clarity and reduced noise.

• Limited launch feedback shows no patients have required follow-up procedures, with most remaining seizure-free.

• Spinal cord paddle lead and SEEG-based drug delivery system in development, with successful initial testing and feasibility studies.

• Next FDA 510(k) submission targeted for facial pain application in the first half of 2025.

Strategic Partnerships and Commercialization

• Zimmer Biomet partnership expanded to include OneRF distribution, with $3M licensing fee and potential milestone payments.

• Mayo Clinic collaboration includes pre-clinical and clinical research, board representation, and first commercial use of Evo electrodes.

• Zimmer Biomet sales force training ongoing, with full rollout expected in 3-4 months.

• Early ablation procedures performed unassisted by Zimmer reps, indicating strong adoption potential.

• Ongoing discussions with potential partners for pain management and drug delivery applications.